Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
Solvency ratios demonstrate a generally stable, though subtly shifting, financial position over the five-year period. While leverage ratios experienced some fluctuation, the company consistently maintained a reasonable ability to meet its financial obligations, though with a noticeable decline in earnings coverage in 2022 and 2023 before a partial recovery.
- Leverage Ratios (Debt to Equity, Debt to Capital, Debt to Assets)
- Debt to equity, debt to capital, and debt to assets ratios all exhibited a moderate increase from 2021 to 2025. The debt to equity ratio rose from 0.46 in 2021 to 0.59 in 2025. Similarly, debt to capital increased from 0.31 to 0.37 over the same period. Debt to assets also showed an upward trend, moving from 0.19 to 0.24. Inclusion of operating lease liabilities resulted in slightly higher ratios, following the same directional trends. These increases suggest a growing reliance on debt financing relative to equity and assets, though the levels remain within a moderate range.
- Financial Leverage
- The financial leverage ratio remained relatively stable between 2021 and 2023, fluctuating around 2.45. A slight increase was observed in 2024 to 2.52, followed by a decrease back to 2.44 in 2025. This indicates a consistent, though modestly variable, amplification of returns to equity holders through the use of debt.
- Coverage Ratios (Interest Coverage, Fixed Charge Coverage)
- Interest coverage and fixed charge coverage ratios experienced a significant decline from 2021 to 2023. Interest coverage plummeted from 125.46 in 2021 to 20.51 in 2023, while fixed charge coverage decreased from 48.16 to 16.50 over the same period. This suggests a substantial reduction in the company’s ability to cover its interest and fixed charges with earnings. However, both ratios demonstrated improvement in 2024 and 2025, reaching 23.10 and 18.47 for interest coverage, and 28.82 for fixed charge coverage, respectively. While these represent a recovery, the levels remain below those observed in 2021, indicating a sustained, though lessening, impact on earnings coverage.
In summary, the observed trends suggest a gradual increase in debt utilization alongside a temporary, but substantial, weakening in earnings coverage, followed by a partial recovery. Continued monitoring of these ratios is recommended to assess the long-term sustainability of the company’s capital structure and its ability to service its debt obligations.
Debt Ratios
Coverage Ratios
Debt to Equity
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans and notes payable | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity1 | ||||||
| Benchmarks | ||||||
| Debt to Equity, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio exhibits a fluctuating pattern over the five-year period. Initially, the ratio increased before decreasing and then increasing again, culminating in the highest value observed in the period.
- Debt to Equity Trend
- In 2021, the debt to equity ratio stood at 0.46. This ratio increased to 0.52 in 2022, indicating a greater proportion of debt financing relative to equity. A subsequent decrease was observed in 2023, with the ratio falling to 0.43. The ratio then rose to 0.51 in 2024, and continued to increase in 2025, reaching 0.59. This represents the most substantial level of debt financing relative to equity throughout the analyzed timeframe.
The increase in the debt to equity ratio in 2022 and, more significantly, in 2025 suggests a growing reliance on debt to finance assets and operations. While not inherently negative, this trend warrants further investigation to assess the company’s ability to service its debt obligations and the potential impact on financial flexibility. The decrease observed in 2023 may indicate a period of debt reduction or increased equity, but this was not sustained.
- Total Debt and Shareholders’ Equity Relationship
- The observed fluctuations in the debt to equity ratio are directly influenced by changes in both total debt and shareholders’ equity. Total debt increased from US$33,751 million in 2021 to US$47,933 million in 2025. Shareholders’ equity also increased over the period, from US$74,023 million to US$81,544 million, but the growth in debt outpaced the growth in equity, contributing to the overall upward trend in the ratio.
The consistent increase in total debt, coupled with a comparatively slower growth in shareholders’ equity, is the primary driver of the observed changes in the debt to equity ratio. Continued monitoring of these figures is recommended to evaluate the long-term sustainability of the company’s capital structure.
Debt to Equity (including Operating Lease Liability)
Johnson & Johnson, debt to equity (including operating lease liability) calculation, comparison to benchmarks
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans and notes payable | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liability | ||||||
| Total debt (including operating lease liability) | ||||||
| Shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Debt to equity (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Equity (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Equity (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The debt to equity ratio, incorporating operating lease liabilities, exhibits a fluctuating pattern over the five-year period. Total debt and shareholders’ equity both experienced increases between 2021 and 2022, but followed divergent paths in subsequent years.
- Debt to Equity Trend
- The debt to equity ratio increased from 0.47 in 2021 to 0.53 in 2022, indicating a greater reliance on debt financing relative to equity. A subsequent decrease to 0.44 was observed in 2023, suggesting a reduction in leverage. However, the ratio rebounded to 0.53 in 2024, remaining at a similar level as 2022. The most significant change occurred in 2025, with the ratio rising to 0.60, representing the highest level observed during the analyzed period.
- Total Debt
- Total debt, including operating lease liabilities, increased from US$34,751 million in 2021 to US$40,959 million in 2022. A notable decrease to US$30,432 million occurred in 2023, followed by an increase to US$37,834 million in 2024. The largest increase in total debt occurred between 2024 and 2025, reaching US$49,333 million.
- Shareholders’ Equity
- Shareholders’ equity showed a modest increase from US$74,023 million in 2021 to US$76,804 million in 2022. A decrease was then recorded in 2023, falling to US$68,774 million. Equity levels recovered in 2024 to US$71,490 million and continued to rise substantially in 2025, reaching US$81,544 million.
The increase in the debt to equity ratio in 2025 is primarily driven by a larger increase in total debt compared to the increase in shareholders’ equity. While equity is growing, the pace of debt accumulation is faster, suggesting a potential shift towards increased financial leverage. The fluctuations observed throughout the period indicate dynamic capital structure management.
Debt to Capital
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans and notes payable | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Shareholders’ equity | ||||||
| Total capital | ||||||
| Solvency Ratio | ||||||
| Debt to capital1 | ||||||
| Benchmarks | ||||||
| Debt to Capital, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio exhibits a generally increasing trend over the observed five-year period. While fluctuations occur, the ratio demonstrates a move from a lower level of leverage to a higher one, particularly in the most recent year.
- Debt to Capital Ratio - Overall Trend
- The debt to capital ratio began at 0.31 in 2021, increased to 0.34 in 2022, decreased slightly to 0.30 in 2023, and then rose again to 0.34 in 2024. The most significant increase occurred between 2024 and 2025, with the ratio reaching 0.37. This indicates a growing reliance on debt financing relative to total capital.
The initial increase from 2021 to 2022 suggests a period of increased borrowing or a decrease in capital. The subsequent dip in 2023 could be attributed to debt reduction or an increase in capital. However, the return to 0.34 in 2024 and the further increase to 0.37 in 2025 indicate that the trend towards higher leverage has reasserted itself.
- Underlying Components
- Total debt increased from US$33,751 million in 2021 to US$47,933 million in 2025. Total capital also increased over the same period, moving from US$107,774 million to US$129,477 million. However, the growth in debt appears to be outpacing the growth in capital, driving the observed increase in the debt to capital ratio.
The consistent increase in the ratio in the latest period warrants further investigation to understand the reasons behind the increased debt levels and their potential impact on the company’s financial flexibility and risk profile.
Debt to Capital (including Operating Lease Liability)
Johnson & Johnson, debt to capital (including operating lease liability) calculation, comparison to benchmarks
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans and notes payable | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liability | ||||||
| Total debt (including operating lease liability) | ||||||
| Shareholders’ equity | ||||||
| Total capital (including operating lease liability) | ||||||
| Solvency Ratio | ||||||
| Debt to capital (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Capital (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Capital (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =
2 Click competitor name to see calculations.
The debt to capital ratio, inclusive of operating lease liabilities, exhibits a fluctuating pattern over the five-year period. Total debt and total capital both increased between 2021 and 2022, followed by a decrease in 2023, and then increases again in 2024 and 2025. However, the rate of increase in total debt appears to be exceeding that of total capital in the later years of the observed period.
- Debt to Capital Ratio - Trend Analysis
- The debt to capital ratio began at 0.32 in 2021, increasing to 0.35 in 2022. A slight decrease was then observed in 2023, with the ratio falling to 0.31. The ratio then rose again to 0.35 in 2024, and continued to increase to 0.38 in 2025. This indicates a growing reliance on debt financing relative to capital over the period, particularly in the most recent two years.
The increase in the debt to capital ratio from 2021 to 2022 suggests increased leverage. The subsequent dip in 2023 could be attributed to debt reduction or an increase in capital. However, the renewed upward trend from 2023 onwards indicates a shift back towards greater financial leverage. The most significant increase in the ratio occurs between 2024 and 2025, suggesting a more pronounced increase in debt relative to capital during that timeframe.
- Total Debt and Total Capital - Comparative Growth
- While both total debt and total capital generally increased over the period, the magnitude of the increases varied. The largest absolute increase in total debt occurred between 2024 and 2025 (US$11,499 million), while the largest absolute increase in total capital also occurred during the same period (US$21,553 million). However, the percentage increase in total debt between 2024 and 2025 (30.3%) was higher than the percentage increase in total capital (19.7%), contributing to the rising debt to capital ratio.
The observed trend suggests a potential increase in financial risk, as the company is utilizing a greater proportion of debt to finance its assets and operations. Continued monitoring of this ratio is recommended to assess the sustainability of the company’s capital structure.
Debt to Assets
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans and notes payable | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets1 | ||||||
| Benchmarks | ||||||
| Debt to Assets, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt-to-assets ratio exhibited a fluctuating pattern over the five-year period. Initially, the ratio increased before decreasing and then increasing again, ultimately reaching its highest point in the observed timeframe.
- Overall Trend
- The debt-to-assets ratio generally trended upward, although not consistently. It began at 0.19 in 2021, rose to 0.21 in 2022, decreased to 0.18 in 2023, increased to 0.20 in 2024, and concluded at 0.24 in 2025. This indicates a growing reliance on debt financing relative to total assets over the period.
- Year-over-Year Changes
- From 2021 to 2022, the ratio increased by 0.02, suggesting an increase in leverage. A subsequent decrease of 0.03 was observed from 2022 to 2023, indicating a reduction in leverage. The ratio then increased by 0.02 from 2023 to 2024, and a more substantial increase of 0.04 occurred from 2024 to 2025. These changes suggest shifts in the company’s capital structure and financing strategies.
- Ratio Magnitude
- Throughout the period, the debt-to-assets ratio remained below 0.25. However, the final value of 0.24 in 2025 represents the highest level observed, suggesting a potentially increased financial risk profile compared to earlier years. The ratio indicates that, in 2025, approximately 24% of the company’s assets were financed by debt.
The observed increases in the debt-to-assets ratio in the later years warrant further investigation to understand the underlying reasons, such as increased investment in assets financed by debt, or changes in debt management policies.
Debt to Assets (including Operating Lease Liability)
Johnson & Johnson, debt to assets (including operating lease liability) calculation, comparison to benchmarks
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Loans and notes payable | ||||||
| Long-term debt, excluding current portion | ||||||
| Total debt | ||||||
| Operating lease liability | ||||||
| Total debt (including operating lease liability) | ||||||
| Total assets | ||||||
| Solvency Ratio | ||||||
| Debt to assets (including operating lease liability)1 | ||||||
| Benchmarks | ||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Debt to Assets (including Operating Lease Liability), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Debt to Assets (including Operating Lease Liability), Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The debt to assets ratio, including operating lease liability, exhibits a fluctuating pattern over the five-year period. Total debt and total assets both increased between 2021 and 2022, followed by a decrease in total assets in 2023, while total debt also decreased. Both metrics then increased in 2024, with a more substantial increase in total debt continuing into 2025.
- Debt to Assets Ratio - Overall Trend
- The debt to assets ratio increased from 0.19 in 2021 to 0.22 in 2022. A subsequent decrease to 0.18 was observed in 2023. The ratio then rose to 0.21 in 2024 and further increased to 0.25 in 2025, representing the highest level within the observed period.
- Debt and Asset Movements
- Between 2021 and 2022, total debt increased by approximately 18%, while total assets grew by roughly 3%. This differential contributed to the increase in the debt to assets ratio. The decrease in total assets in 2023, coupled with a decrease in total debt, led to a reduction in the ratio. The subsequent increases in both debt and assets in 2024 and 2025 resulted in a renewed upward trend for the ratio, with the increase in debt outpacing the increase in assets in 2025.
The increase in the debt to assets ratio in 2025 suggests a greater reliance on debt financing relative to the company’s asset base. The fluctuations observed throughout the period indicate a dynamic capital structure, potentially influenced by investment activities, financing decisions, and overall business performance.
Financial Leverage
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Total assets | ||||||
| Shareholders’ equity | ||||||
| Solvency Ratio | ||||||
| Financial leverage1 | ||||||
| Benchmarks | ||||||
| Financial Leverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Financial Leverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Financial Leverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial leverage of the company, as measured by the ratio of total assets to shareholders’ equity, exhibits relative stability over the observed five-year period. While fluctuations are present, the ratio remains consistently around 2.4 to 2.5, indicating a consistent reliance on financial leverage to fund assets.
- Overall Trend
- The financial leverage ratio demonstrates a minor initial decrease from 2.46 in 2021 to 2.44 in 2022. It then remains stable at 2.44 in 2023 before increasing to 2.52 in 2024. A slight decrease is then observed in 2025, returning to 2.44. This suggests a generally consistent capital structure with limited significant shifts in the proportion of assets financed by equity.
- Year-over-Year Changes
- The most notable change occurs between 2023 and 2024, with an increase of 0.08 in the financial leverage ratio. This indicates a greater reliance on debt financing relative to equity during that period. The subsequent decrease in 2025 partially offsets this increase, suggesting a recalibration of the capital structure.
- Relationship to Asset and Equity Movements
- Total assets decreased from 2021 to 2023, then increased in 2024 and 2025. Shareholders’ equity followed a similar pattern, decreasing from 2021 to 2023 and increasing in 2024 and 2025. The relatively stable leverage ratio suggests that changes in assets and equity have generally moved in tandem, maintaining a consistent proportion of debt to equity financing.
In conclusion, the company maintains a consistent level of financial leverage. The observed fluctuations appear to be moderate and do not indicate a substantial shift in the company’s financing strategy. The ratio’s stability suggests a predictable approach to capital structure management.
Interest Coverage
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings | ||||||
| Less: Net earnings from discontinued operations, net of tax | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense, net of portion capitalized | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Solvency Ratio | ||||||
| Interest coverage1 | ||||||
| Benchmarks | ||||||
| Interest Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Interest Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Interest Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =
2 Click competitor name to see calculations.
The interest coverage ratio exhibited considerable fluctuation over the observed five-year period. Initial values were strong, but a significant decline occurred before a subsequent recovery.
- Earnings Before Interest and Tax (EBIT)
- EBIT demonstrated a decrease from US$22,959 million in 2021 to US$22,001 million in 2022. A more substantial reduction followed in 2023, falling to US$15,834 million. A moderate increase to US$17,442 million was noted in 2024, culminating in a significant rise to US$33,552 million in 2025.
- Interest Expense
- Interest expense increased from US$183 million in 2021 to US$276 million in 2022. This upward trend continued with a substantial increase to US$772 million in 2023, followed by a slight decrease to US$755 million in 2024. Further growth was observed in 2025, reaching US$971 million.
- Interest Coverage Ratio
- The interest coverage ratio began at a high of 125.46 in 2021. A considerable decrease was observed in 2022, falling to 79.71. This decline accelerated in 2023, with the ratio reaching 20.51. A modest improvement occurred in 2024, with the ratio rising to 23.10. The most recent year, 2025, showed a further increase to 34.55, indicating improved ability to meet interest obligations.
The interplay between EBIT and interest expense significantly impacted the interest coverage ratio. The substantial decrease in EBIT in 2023, coupled with rising interest expense, led to the lowest ratio value during the period. The recovery in EBIT during 2025, alongside continued, though moderated, increases in interest expense, resulted in a strengthened interest coverage position.
Fixed Charge Coverage
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net earnings | ||||||
| Less: Net earnings from discontinued operations, net of tax | ||||||
| Add: Income tax expense | ||||||
| Add: Interest expense, net of portion capitalized | ||||||
| Earnings before interest and tax (EBIT) | ||||||
| Add: Operating lease costs | ||||||
| Earnings before fixed charges and tax | ||||||
| Interest expense, net of portion capitalized | ||||||
| Operating lease costs | ||||||
| Fixed charges | ||||||
| Solvency Ratio | ||||||
| Fixed charge coverage1 | ||||||
| Benchmarks | ||||||
| Fixed Charge Coverage, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Fixed Charge Coverage, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Fixed Charge Coverage, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =
2 Click competitor name to see calculations.
The company’s fixed charge coverage exhibited considerable fluctuation over the five-year period. Initial values were strong, but a notable decline occurred before a subsequent recovery. Earnings before fixed charges and tax, and fixed charges themselves, both contributed to these observed changes.
- Earnings Before Fixed Charges and Tax
- Earnings before fixed charges and tax decreased from US$23,259 million in 2021 to US$22,301 million in 2022, representing a modest decline. A more substantial decrease was observed in 2023, falling to US$16,034 million. A partial recovery occurred in 2024, with earnings reaching US$17,642 million, followed by a significant increase to US$33,752 million in 2025.
- Fixed Charges
- Fixed charges increased from US$483 million in 2021 to US$576 million in 2022. This upward trend continued in 2023, reaching US$972 million, before decreasing slightly to US$955 million in 2024. A further increase was noted in 2025, with fixed charges reaching US$1,171 million.
- Fixed Charge Coverage Ratio
- The fixed charge coverage ratio began at 48.16 in 2021 and decreased to 38.72 in 2022. The most significant decline occurred in 2023, with the ratio falling to 16.50. A modest improvement was seen in 2024, with the ratio increasing to 18.47. The ratio experienced a substantial increase in 2025, reaching 28.82. The fluctuations in the ratio largely correspond to the changes in earnings before fixed charges and tax, with the increase in fixed charges partially offsetting the impact of earnings changes.
The substantial increase in earnings before fixed charges and tax in 2025, coupled with a moderate increase in fixed charges, resulted in a significant improvement in the fixed charge coverage ratio. Prior to 2025, the ratio demonstrated vulnerability to declines in earnings, highlighting a sensitivity to profitability. The company’s ability to comfortably meet its fixed obligations appears to have strengthened considerably in the most recent year.